Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine‑tolerance molecular markers following 18 years of artemisinin‑based combination therapy use in Mpumalanga Province, South Africa (2001–2018)

dc.contributor.authorRaman, Jaishree
dc.contributor.authorKagoro, Frank M.
dc.contributor.authorMabuza, Aaron
dc.contributor.authorMalatje, Gillian
dc.contributor.authorReid, Anthony
dc.contributor.authorBarnes, Karen I.
dc.date.accessioned2019-11-27T08:52:03Z
dc.date.available2019-11-27T08:52:03Z
dc.date.issued2019-08-22
dc.description.abstractBACKGROUND : The ability of Plasmodium falciparum parasites to develop resistance to widely used anti-malarials threatens malaria control and elimination efforts. Regular drug efficacy monitoring is essential for ensuring effective treatment policies. In low transmission settings where therapeutic efficacy studies are often not feasible, routine surveillance for molecular markers associated with anti-malarial resistance provides an alternative for the early detection of emerging resistance. Such a longitudinal survey of changes in the prevalence of selected molecular markers of resistance was conducted in the malaria-endemic regions of Mpumalanga Province, South Africa, where malaria elimination at a district-level is being pursued. METHODS : Molecular analyses to determine the prevalence of alleles associated with resistance to lumefantrine (mdr86N, crt76K and mdr1 copy number variation) and sulfadoxine–pyrimethamine (dhfr triple, dhps double, SP quintuple) were conducted between 2001 and 2018, while artemisinin resistance markers (kelch13 mutations) were assessed only in 2018. RESULTS : Parasite DNA was successfully amplified from 1667/2393 (70%) of malaria-positive rapid diagnostic tests routinely collected at primary health care facilities. No artemisinin resistance-associated kelch13 mutations nor amplification of the mdr1 gene copy number associated with lumefantrine resistance were observed. However, prevalence of both the mdr86N and crt76K alleles increased markedly over the study period, with all isolates collected in 2018 carrying these markers. SP quintuple mutation prevalence increased steadily from 14% in 2001 to 96% in 2018. Mixed alleles at any of the codons assessed were rare by 2018. CONCLUSION : No kelch13 mutations confirmed or suspected to be associated with artemisinin resistance were identified in 2018. Although parasites carrying the mdr86N and crt76K alleles associated with reduced lumefantrine susceptibility were strongly selected for over the study period, nearing fixation by 2018, the marker for lumefantrine resistance, namely increased mdr1 copy number, was not observed in this study. The increase in mdr86N and crt76Ken_ZA
dc.description.departmentSchool of Health Systems and Public Health (SHSPH)en_ZA
dc.description.librarianam2019en_ZA
dc.description.sponsorshipThe SAMRC, the NICD the WHO/TDR, GMP and WHO/AFRO.en_ZA
dc.description.urihttp://www.malariajournal.comen_ZA
dc.identifier.citationRaman, J., Kagoro, F.M., Mabuza, A. et al. 2019, 'Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine‑tolerance molecular markers following 18 years of artemisinin‑based combination therapy use in Mpumalanga Province, South Africa (2001–2018)', Malaria Journal. vol.18, art. 280, pp. 1-12.en_ZA
dc.identifier.issn1475-2875
dc.identifier.other10.1186/s12936-019-2911-y
dc.identifier.urihttp://hdl.handle.net/2263/72406
dc.language.isoenen_ZA
dc.publisherBioMed Centralen_ZA
dc.rights© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.en_ZA
dc.subjectResistanceen_ZA
dc.subjectKelch13en_ZA
dc.subjectMalariaen_ZA
dc.subjectPlasmodium falciparumen_ZA
dc.subjectMutationsen_ZA
dc.subjectMpumalanga Province, South Africaen_ZA
dc.subjectArtemisinin-based combination therapy (ACT)en_ZA
dc.subjectDihydropteroate synthetase (dhps)en_ZA
dc.subjectCodon 86 of the P. falciparum multi-drug resistance gene 1 (mdr186)en_ZA
dc.subjectCodon 76 of the P. falciparum chloroquine resistance transporter gene (crt76)en_ZA
dc.subjectEfficacyen_ZA
dc.subjectMutationsen_ZA
dc.subjectSurveillanceen_ZA
dc.subjectPolymorphismen_ZA
dc.subjectIdentificationen_ZA
dc.subjectImplementationen_ZA
dc.subjectPolymerase chain reaction (PCR)en_ZA
dc.subjectDrug resistanceen_ZA
dc.subjectSulfadoxine-pyrimethamineen_ZA
dc.titleAbsence of kelch13 artemisinin resistance markers but strong selection for lumefantrine‑tolerance molecular markers following 18 years of artemisinin‑based combination therapy use in Mpumalanga Province, South Africa (2001–2018)en_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Raman_Absence_2019.pdf
Size:
1.81 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: